The Experts below are selected from a list of 123360 Experts worldwide ranked by ideXlab platform

Roberto P Falcao - One of the best experts on this subject based on the ideXlab platform.

Atsuo Ogura - One of the best experts on this subject based on the ideXlab platform.

  • somatic Donor Cell type correlates with embryonic but not extra embryonic gene expression in postimplantation cloned embryos
    PLOS ONE, 2013
    Co-Authors: Ryutaro Hirasawa, Kimiko Inoue, Atsuo Ogura, Shogo Matoba
    Abstract:

    The great majority of embryos generated by somatic Cell nuclear transfer (SCNT) display defined abnormal phenotypes after implantation, such as an increased likelihood of death and abnormal placentation. To gain better insight into the underlying mechanisms, we analyzed genome-wide gene expression profiles of day 6.5 postimplantation mouse embryos cloned from three different Cell types (cumulus Cells, neonatal Sertoli Cells and fibroblasts). The embryos retrieved from the uteri were separated into embryonic (epiblast) and extraembryonic (extraembryonic ectoderm and ectoplacental cone) tissues and were subjected to gene microarray analysis. Genotype- and sex-matched embryos produced by in vitro fertilization were used as controls. Principal component analysis revealed that whereas the gene expression patterns in the embryonic tissues varied according to the Donor Cell type, those in extraembryonic tissues were relatively consistent across all groups. Within each group, the embryonic tissues had more differentially expressed genes (DEGs) (>2-fold vs. controls) than did the extraembryonic tissues (P<1.0×10–26). In the embryonic tissues, one of the common abnormalities was upregulation of Dlk1, a paternally imprinted gene. This might be a potential cause of the occasional placenta-only conceptuses seen in SCNT-generated mouse embryos (1–5% per embryos transferred in our laboratory), because dysregulation of the same gene is known to cause developmental failure of embryos derived from induced pluripotent stem Cells. There were also some DEGs in the extraembryonic tissues, which might explain the poor development of SCNT-derived placentas at early stages. These findings suggest that SCNT affects the embryonic and extraembryonic development differentially and might cause further deterioration in the embryonic lineage in a Donor Cell-specific manner. This could explain Donor Cell-dependent variations in cloning efficiency using SCNT.

  • effects of Donor Cell type and genotype on the efficiency of mouse somatic Cell cloning
    Biology of Reproduction, 2003
    Co-Authors: Kimiko Inoue, Narumi Ogonuki, Keiji Mochida, Yoshie Yamamoto, Kaoru Takano, Takashi Kohda, Fumitoshi Ishino, Atsuo Ogura
    Abstract:

    Abstract Although it is widely assumed that the Cell type and genotype of the Donor Cell affect the efficiency of somatic Cell cloning, little systematic analysis has been done to verify this assumption. The present study was undertaken to examine whether Donor Cell type, Donor genotype, or a combination thereof increased the efficiency of mouse cloning. Initially we assessed the developmental ability of embryos that were cloned from cumulus or immature Sertoli Cells with six different genotypes (i.e., 2 × 6 factorial). Significantly better cleavage rates were obtained with cumulus Cells than with Sertoli Cells (P < 0.005, two-way ANOVA), which probably was due to the superior Cell-cycle synchrony of cumulus Cells at G0/G1. After embryo transfer, there was a significant effect of Cell type on the birth rate, with Sertoli Cells giving the better result (P < 0.005). Furthermore, there was a significant interaction (P < 0.05) between the Cell type and genotype, which indicates that cloning efficiency is dete...

  • effects of Donor Cell type and genotype on the efficiency of mouse somatic Cell cloning
    Biology of Reproduction, 2003
    Co-Authors: Kimiko Inoue, Narumi Ogonuki, Keiji Mochida, Yoshie Yamamoto, Kaoru Takano, Takashi Kohda, Fumitoshi Ishino, Atsuo Ogura
    Abstract:

    Although it is widely assumed that the Cell type and genotype of the Donor Cell affect the efficiency of somatic Cell cloning, little systematic analysis has been done to verify this assumption. The present study was undertaken to examine whether Donor Cell type, Donor genotype, or a combination thereof increased the efficiency of mouse cloning. Initially we assessed the developmental ability of embryos that were cloned from cumulus or immature Sertoli Cells with six different genotypes (i.e., 2 x 6 factorial). Significantly better cleavage rates were obtained with cumulus Cells than with Sertoli Cells (P < 0.005, two-way ANOVA), which probably was due to the superior Cell-cycle synchrony of cumulus Cells at G0/G1. After embryo transfer, there was a significant effect of Cell type on the birth rate, with Sertoli Cells giving the better result (P < 0.005). Furthermore, there was a significant interaction (P < 0.05) between the Cell type and genotype, which indicates that cloning efficiency is determined by a combination of these two factors. The highest mean birth rate (10.8 +/- 2.1%) was obtained with (B6 x 129)F1 Sertoli Cells. In the second series of experiments, we examined whether the developmental ability of clones with the wild-type genotype (JF1) was improved when combined with the 129 genotype. Normal pups were cloned from cumulus and immature Sertoli Cells of the (129 x JF1)F1 and (JF1 x 129)F1 genotypes, whereas no pups were born from Cells with the (B6 x JF1)F1 genotype. The present study clearly demonstrates that the efficiency of somatic Cell cloning, and in particular fetal survival after embryo transfer, may be improved significantly by choosing the appropriate combinations of Cell type and genotype.

Fabrisia Ambrosio - One of the best experts on this subject based on the ideXlab platform.

  • neuromuscular electrical stimulation as a method to maximize the beneficial effects of muscle stem Cells transplanted into dystrophic skeletal muscle
    PLOS ONE, 2013
    Co-Authors: Giovanna Distefano, Johnny Huard, Ricardo Ferrari, Christopher Weiss, Bridget M Deasy, Michael L Boninger, Kelley G Fitzgerald, Fabrisia Ambrosio
    Abstract:

    Cellular therapy is a potential approach to improve the regenerative capacity of damaged or diseased skeletal muscle. However, its clinical use has often been limited by impaired Donor Cell survival, proliferation and differentiation following transplantation. Additionally, functional improvements after transplantation are all-too-often negligible. Because the host microenvironment plays an important role in the fate of transplanted Cells, methods to modulate the microenvironment and guide Donor Cell behavior are warranted. The purpose of this study was to investigate whether the use of neuromuscular electrical stimulation (NMES) for 1 or 4 weeks following muscle-derived stem Cell (MDSC) transplantation into dystrophic skeletal muscle can modulate the fate of Donor Cells and enhance their contribution to muscle regeneration and functional improvements. Animals submitted to 4 weeks of NMES after transplantation demonstrated a 2-fold increase in the number of dystrophin+ myofibers as compared to control transplanted muscles. These findings were concomitant with an increased vascularity in the MDSC+NMES group when compared to non-stimulated counterparts. Additionally, animals subjected to NMES (with or without MDSC transplantation) presented an increased maximal specific tetanic force when compared to controls. Although Cell transplantation and/or the use of NMES resulted in no changes in fatigue resistance, the combination of both MDSC transplantation and NMES resulted in a faster recovery from fatigue, when compared to non-injected and non-stimulated counterparts. We conclude that NMES is a viable method to improve MDSC engraftment, enhance dystrophic muscle strength, and, in combination with MDSC transplantation, improve recovery from fatigue. These findings suggest that NMES may be a clinically-relevant adjunct approach for Cell transplantation into skeletal muscle.

  • neuromuscular electrical stimulation as a method to maximize the beneficial effects of muscle stem Cells transplanted into dystrophic skeletal muscle
    PLOS ONE, 2013
    Co-Authors: Giovanna Distefano, Johnny Huard, Ricardo Ferrari, Christopher Weiss, Bridget M Deasy, Michael L Boninger, Kelley G Fitzgerald, Fabrisia Ambrosio
    Abstract:

    Cellular therapy is a potential approach to improve the regenerative capacity of damaged or diseased skeletal muscle. However, its clinical use has often been limited by impaired Donor Cell survival, proliferation and differentiation following transplantation. Additionally, functional improvements after transplantation are all-too-often negligible. Because the host microenvironment plays an important role in the fate of transplanted Cells, methods to modulate the microenvironment and guide Donor Cell behavior are warranted. The purpose of this study was to investigate whether the use of neuromuscular electrical stimulation (NMES) for 1 or 4 weeks following muscle-derived stem Cell (MDSC) transplantation into dystrophic skeletal muscle can modulate the fate of Donor Cells and enhance their contribution to muscle regeneration and functional improvements. Animals submitted to 4 weeks of NMES after transplantation demonstrated a 2-fold increase in the number of dystrophin+ myofibers as compared to control transplanted muscles. These findings were concomitant with an increased vascularity in the MDSC+NMES group when compared to non-stimulated counterparts. Additionally, animals subjected to NMES (with or without MDSC transplantation) presented an increased maximal specific tetanic force when compared to controls. Although Cell transplantation and/or the use of NMES resulted in no changes in fatigue resistance, the combination of both MDSC transplantation and NMES resulted in a faster recovery from fatigue, when compared to non-injected and non-stimulated counterparts. We conclude that NMES is a viable method to improve MDSC engraftment, enhance dystrophic muscle strength, and, in combination with MDSC transplantation, improve recovery from fatigue. These findings suggest that NMES may be a clinically-relevant adjunct approach for Cell transplantation into skeletal muscle.

Ismael Buno - One of the best experts on this subject based on the ideXlab platform.

  • mutation of the npm1 gene contributes to the development of Donor Cell derived acute myeloid leukemia after unrelated cord blood transplantation for acute lymphoblastic leukemia
    Human Pathology, 2013
    Co-Authors: Gabriela Rodriguezmacias, Carolina Martinezlaperche, Jorge Gayoso, Victor Noriega, D P Serrano, Pascual Balsalobre, Cristina Munozmartinez, Jose Luis Diezmartin, Ismael Buno
    Abstract:

    Donor Cell leukemia (DCL) is a rare but severe complication after allogeneic stem Cell transplantation. Its true incidence is unknown because of a lack of correct recognition and reporting, although improvements in molecular analysis of Donor-host chimerism are contributing to a better diagnosis of this complication. The mechanisms of leukemogenesis are unclear, and multiple factors can contribute to the development of DCL. In recent years, cord blood has emerged as an alternative source of hematopoietic progenitor Cells, and at least 12 cases of DCL have been reported after unrelated cord blood transplantation. We report a new case of DCL after unrelated cord blood transplantation in a 44-year-old woman diagnosed as having acute lymphoblastic leukemia with t(1;19) that developed acute myeloid leukemia with normal karyotype and nucleophosmin (NPM1) mutation in Donor Cells. To our knowledge, this is the first report of NPM1 mutation contributing to DCL development.

Huo Hongguang - One of the best experts on this subject based on the ideXlab platform.